US20230270811A1 - Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising agastache rugosa and licorice extract - Google Patents
Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising agastache rugosa and licorice extract Download PDFInfo
- Publication number
- US20230270811A1 US20230270811A1 US17/935,043 US202217935043A US2023270811A1 US 20230270811 A1 US20230270811 A1 US 20230270811A1 US 202217935043 A US202217935043 A US 202217935043A US 2023270811 A1 US2023270811 A1 US 2023270811A1
- Authority
- US
- United States
- Prior art keywords
- inhibition
- agastache rugosa
- extract
- licorice
- respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000004510 Agastache rugosa Species 0.000 title claims abstract description 123
- 235000010686 Agastache rugosa Nutrition 0.000 title claims abstract description 123
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 36
- 239000000428 dust Substances 0.000 title claims abstract description 29
- 229940069445 licorice extract Drugs 0.000 title abstract description 42
- 239000000203 mixture Substances 0.000 title abstract description 34
- 230000002265 prevention Effects 0.000 title abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 92
- 230000005764 inhibitory process Effects 0.000 claims abstract description 68
- 230000000694 effects Effects 0.000 claims abstract description 51
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims abstract description 21
- 102100022338 Integrin alpha-M Human genes 0.000 claims abstract description 21
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 21
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims abstract description 19
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims abstract description 19
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims abstract description 19
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims abstract description 19
- 206010011224 Cough Diseases 0.000 claims abstract description 17
- 102000003566 TRPV1 Human genes 0.000 claims abstract description 17
- 101150016206 Trpv1 gene Proteins 0.000 claims abstract description 17
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims abstract description 16
- 102100022496 Mucin-5AC Human genes 0.000 claims abstract description 16
- 206010036790 Productive cough Diseases 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 208000024794 sputum Diseases 0.000 claims abstract description 15
- 210000003802 sputum Anatomy 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000009467 reduction Effects 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010006451 bronchitis Diseases 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 13
- 206010014561 Emphysema Diseases 0.000 claims description 10
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 7
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 6
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 201000009267 bronchiectasis Diseases 0.000 claims description 6
- 208000007451 chronic bronchitis Diseases 0.000 claims description 6
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims description 6
- 201000009890 sinusitis Diseases 0.000 claims description 6
- 241000202807 Glycyrrhiza Species 0.000 abstract description 83
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 83
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 83
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 83
- 229940010454 licorice Drugs 0.000 abstract description 83
- 238000002156 mixing Methods 0.000 abstract description 42
- 230000001603 reducing effect Effects 0.000 abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241000698291 Rugosa Species 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241001529821 Agastache Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000010805 cDNA synthesis kit Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003245 coal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000010881 fly ash Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000003915 air pollution Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000002803 fossil fuel Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150031922 MUC5AC gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a composition for the prevention or treatment of respiratory diseases containing an Agastache rugosa and licorice extract as an active ingredient, and more specifically, the present invention relates to a composition for the prevention or treatment of respiratory diseases caused by fine dust containing an extract, in which Agastache rugosa and licorice are mixed at a weight ratio of 1:1 to 6:1, as an active ingredient.
- Fine dust refers to particulate matter less than 10 ⁇ m in diameter (PM10) among the total suspended particles in the air, and it is known to cause diseases such as respiratory diseases, cardiovascular diseases, and the like, and it is also associated with increased mortality. Most of the fine dust is generated by the combustion of fossil fuels, and as it is not filtered by the mucous membrane and cilia of the nose and airways, it penetrates into the alveoli and bronchi to inhibit lung function.
- COPD chronic obstructive pulmonary disease
- bronchitis pneumonia, tuberculosis, lung cancer, pulmonary fibrosis, chronic lung diseases, respiratory distress syndrome, upper respiratory tract infection, and the like
- various diseases such as cardiovascular diseases, skin diseases, and the like.
- the present invention as a result of diligently making efforts to develop an effective therapeutic agent for respiratory diseases caused by fine dust, it was confirmed that the efficacy of an Agastache rugosa and licorice extract was maximized at a specific mixing ratio.
- the present invention was completed by confirming that lung inflammation, cough, and sputum that characterize the infiltration of neutrophils, which is a respiratory symptom caused by fine dust, were effectively suppressed.
- An object of the present invention is to provide a pharmaceutical composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- Another object of the present invention is to provide a health functional food composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- the present invention provides a health functional food composition for preventing or ameliorating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- the respiratory disease may be induced by inhalation of fine dust and may be one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
- COPD chronic obstructive pulmonary disease
- the Agastache rugosa and licorice extract may be a mixture of an Agastache rugosa extract and a licorice extract, or an Agastache rugosa and licorice complex extract.
- the Agastache rugosa and licorice extract may be mixed with Agastache rugosa and licorice at a weight ratio of 1:1 to 6:1.
- the Agastache rugosa and licorice extract may be extracted using one or more solvents selected from the group consisting of water, ethanol, alcohol having a carbon number of 1 to 4. hexane, and ethyl acetate.
- the Agastache rugosa and licorice complex extract may reduce cough through inhibition of TRPV1 activity.
- the Agastache rugosa and licorice complex extract may suppress inflammation in the lungs through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction.
- the Agastache rugosa and licorice complex extract may suppress sputum production through inhibition of MUC5AC activity.
- the Agastache rugosa and licorice extract of the present invention has efficacies of reducing cough through inhibition of TRPV1 activity, reducing lung inflammation through inhibition of CXCR1 and CXCR2 activities and GR-1+CD11b+ cell ratio reduction, and suppressing sputum production through inhibition of MUC5AC activity.
- the efficacy of the complex mixture of Agastache rugosa and licorice is maximized at a specific mixing ratio, it can be widely utilized as a composition for the prevention or treatment of respiratory diseases caused by fine dust.
- FIG. 1 is a set of data showing the degree of inhibition of TRPV1 activity according to the mixing ratios of licorice and Agastache rugosa .
- A is data showing the percentage of inhibition of TRPV1 mRNA expression
- B is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups
- C is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa.
- FIG. 2 is a set of data showing the degree of inhibition of CXCR1 activity according to the mixing ratios of licorice and Agastache rugosa .
- A is data showing the percentage of inhibition of CXCR1 mRNA expression
- B is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups
- C is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa.
- FIG. 3 is a set of data showing the degree of inhibition of CXCR2 activity according to the mixing ratios of licorice and Agastache rugosa .
- A is data showing the percentage of inhibition of CXCR2 mRNA expression
- B is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups
- C is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa.
- FIG. 4 is a set of data showing the degree of inhibition of GR-1+CD11b+ cell activity according to the mixing ratios of licorice and Agastache rugosa .
- A is data showing the percentage of inhibition of GR-1+CD11b+ cells
- B is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups
- C is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa.
- FIG. 5 is a set of data showing the degree of inhibition of MUC5AC activity according to the mixing ratios of licorice and Agastache rugosa .
- A is data showing the percentage of inhibition of MUC5AC mRNA expression
- B is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups
- C is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa.
- the present invention relates to a pharmaceutical composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- the respiratory disease may be induced by inhalation of fine dust and may be one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, pneumonia, bronchial asthma, bronchiectasis, emphysema, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
- COPD chronic obstructive pulmonary disease
- the Agastache rugosa and licorice extract may be mixed with Agastache rugosa and licorice at a weight ratio of 1:1 to 6:1, and preferably, at a weight ratio of 4:1.
- an Agastache rugosa extract and a licorice extract may be prepared separately and then used by mixing depending on the purpose.
- the pharmaceutical composition for preventing or treating a respiratory disease according to the present invention may further include a natural extract that has an effect of preventing, treating, or ameliorating respiratory diseases, a fraction thereof, or a compound thereof, in addition to Agastache rugosa and licorice.
- the Agastache rugosa and licorice extract of the present invention may be extracted by ethanol.
- an Agastache rugosa and licorice extract was prepared using ethanol such that the mixing ratio of Agastache rugosa to licorice was 1:1 to 6:1. respectively, and as Experimental Example 4 and comparative example, an Agastache rugosa -only extract and a licorice-only extract were prepared.
- the efficacy of an Agastache rugosa and licorice extract on preventing or ameliorating various respiratory symptoms caused by fine dust was confirmed.
- TRPV1 inhibitory activity was high in the treatment groups of Agastache rugosa and licorice complex extracts (Experimental Examples 1 to 3), compared to an Agastache rugosa -only extract (Experimental Example 4) and a licorice-only extract (Comparative Example).
- the efficacy of suppressing cough was maximized in a complex extract in which Agastache rugosa and licorice were mixed at a ratio of 4:1 ( FIG. 1 ).
- the Agastache rugosa and licorice extract since it was confirmed that the Agastache rugosa and licorice extract not only inhibited CXCR1 and CXCR2 expressions, but also significantly reduced the ratio of CD11b+/Gr-1+ cells (neutrophils) in the lung tissue, it was confirmed to have efficacy for ameliorating the infiltration of neutrophils, which is a characteristic of respiratory diseases caused by fine dust.
- the Agastache rugosa and licorice extract of the present invention can treat or ameliorate respiratory diseases through reducing cough through inhibition of TRPV1 activity; reducing lung inflammation through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction; and suppressing sputum production through inhibition of MUC5AC activity, the Agastache rugosa and licorice extract of the present invention can be widely utilized in the prevention or treatment of respiratory diseases.
- the pharmaceutical composition of the present invention may be formulated into various forms according to respective conventional methods.
- it may be formulated into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and the like, and may be used in the form of external preparations, suppositories, and sterile injectable solutions.
- pharmaceutically acceptable carriers, excipients, and diluents may be further included.
- it may be formulated and used in the form of external preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like, and sterile injectable solutions according to a conventional method.
- Examples of the carriers, excipients, and diluents include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, mineral oil, and the like.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like, which are generally used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. These solid preparations are prepared by mixing at least one excipient in the composition, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition, lubricants such as magnesium stearate talc are used in addition to simple excipients.
- Liquid preparations for oral use may include suspensions, intravenous solutions, emulsions, syrups, and the like, and in addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives, and the like may be included.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations. suppositories, and the like.
- non-aqueous solvents and suspensions propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used.
- bases of suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, and the like may be used.
- the term ‘administration’ means to provide the pharmaceutical composition of the present invention to a subject in any suitable way.
- the pharmaceutical composition of the present invention may be administered at an amount of an active ingredient or a pharmaceutical composition that induces a biological or medical response in a tissue system of an animal or a human, which is considered by researchers, veterinarians, doctors, or other clinicians, that is, at a clinically effective amount which is an amount that induces relief of symptoms of the disease or disorder to be treated. It is apparent to those skilled in the art that the therapeutically effective dose and the number of administrations with respect to the pharmaceutical composition of the present invention will vary depending on the desired effect.
- the optimal dosage to be administered may be easily determined by those skilled in the art, and may be adjusted depending on the type of disease, the severity of the disease, the content of active ingredients and other ingredients contained in the composition, the type of formulation, the patient's age, weight, general health status, gender, and diet, administration time, routes of administration and secretion rates of the composition, treatment period, and various factors including drugs used concurrently.
- the pharmaceutical composition of the present invention may be administered at an amount of 1 mg/kg/day to 10.000 mg/kg/day, may be administered once a day, or may be divided and administered several times.
- the present invention relates to a health functional food composition for preventing or ameliorating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- the Agastache rugosa and licorice extract of the present invention has efficacies of suppressing cough, suppressing lung inflammation through inhibiting the infiltration of neutrophils, and suppressing sputum, it may be used in a health functional food composition for preventing or ameliorating a respiratory disease, which is specifically as described above.
- the formulation of the health functional food of the present invention may be in the form of powders, granules, pills, tablets, and capsules, as well as general foods or beverages.
- the type of the food is not particularly limited, and examples of foods to which the substance may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, and dairy products including ice cream, various soups, beverages, teas, drinks, alcoholic beverages, vitamin complexes, and the like, and may contain all foods in the conventional meanings.
- the composition when preparing a food or beverage, may be added at an amount of 15 parts by weight or less, and preferably, 10 parts by weight or less, based on 100 parts by weight of the raw material.
- the above amount may be the same or below the above range, and since the composition of the present invention has no problem in terms of safety, it may be used at an amount at or above the above range.
- the beverage among the health functional foods according to the present invention may contain various flavoring agents, natural carbohydrates, or the like, as additional components as in a conventional beverage.
- the natural carbohydrates described above may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, erythritol, and the like.
- sweetener natural sweeteners such as thaumatin and a stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like may be used.
- the ratio of the natural carbohydrate may be about 0.01 g to 0.04 g, and preferably, about 0.02 g to 0.03 g per 100 mL of the beverage according to the present invention.
- the health functional food according to the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, and carbonating agents used in carbonated beverages.
- the composition for improving sleep according to the present invention may contain natural fruit juice, fruit juice drinks, and fruit flesh for the production of vegetable drinks. These ingredients may be used independently or in combination. The ratio of these additives is not limited, but is generally selected from the range of 0.01 to 0.1 parts by weight compared to 100 parts by weight of the health functional food of the present invention.
- Example 2 It was performed in the same manner as in Example 1, except that 100 g of dried licorice was used, and as a result, a licorice extract was prepared.
- Example 2 It was performed in the same manner as in Example 1, except that 50 g of dried Agastache rugosa and 50 g of dried licorice were used, and as a result, an Agastache rugosa and licorice extract (ratio of 1:1) was prepared.
- Example 2 It was performed in the same manner as in Example 1, except that 80 g of dried Agastache rugosa and 20 g of dried licorice were used, and as a result, an Agastache rugosa and licorice extract (ratio of 4:1) was prepared.
- Example 2 It was performed in the same manner as in Example 1, except that 86 g of dried Agastache rugosa and 14 g of dried licorice were used, and as a result, an Agastache rugosa and licorice extract (ratio of 6:1) was prepared.
- the expression level of TRPV-1 known as a cough receptor was determined in order to confirm the cough-reducing efficacy of the Agastache rugosa and licorice extract.
- MH-S cells which are alveolar macrophages were cultured in RPMI 1640 medium containing 10% FBS, 100 U/mL of penicillin, and 100 ⁇ g/mL of streptomycin at a condition of 37° C. and 5% CO 2 .
- Cells were placed in a 6-well plate to be at 5 ⁇ 10 5 cells/mL, and a mixture (CFA) that was prepared by dissolving 50 mg/mL of coal and 50 mg/mL of fly ash in DMSO was treated at a concentration of 200 ⁇ g/mL to induce a reaction by fine dust for 1 hour.
- CFA mixture
- Example 4 the Agastache rugosa -only extract (Experimental Example 4), the licorice-only extract (Comparative Example), and the Agastache rugosa and licorice extracts (Experimental Examples 1 to 3) prepared in Example 1 above were treated at a concentration of 60 ⁇ g/mL in a solution in which DMSO and PBS were mixed at 1:1 to culture for 6 hours at a condition of 37° C. and 5% CO 2 , respectively.
- a cDNA synthesis kit ReverTraAce cDNA Synthesis kit; Toyobo, Japan.
- qPCR was performed at a condition of 2 minutes at 50° C., 2 minutes at 95° C., 15 seconds at 95° C. for 40 repetitions, and 1 minute at 60° C.
- TaqMan-TRPV1 (Mm01246302_m1, FAM-MGB dye-labeled) and GAPDH (Mm99999915_g1, FAM-MGB dye-labeled) were purchased from Thermo Fisher Scientific to perform qPCR.
- Expected percentage of inhibition (%) [(measured percentage of inhibition of Agastache rugosa -only extract (%)) ⁇ mixing amount of Agastache rugosa ( g )/100]+[(measured percentage of inhibition of licorice-only extract (%)) ⁇ mixing amount of licorice ( g )/100] [Mathematical Formula 1]
- TRPV1 inhibitory activity was increased depending on the mixing of the Agastache rugosa extract and the licorice extract, and in particular, it was confirmed that the TRPV1 inhibitory activity was most excellent when the Agastache rugosa and licorice extract was mixed at a weight ratio of 4:1.
- CXCR1 and CXCR2 expression levels were determined in order to confirm whether the Agastache rugosa and licorice complex extract inhibits lung inflammation.
- MH-S cells which are alveolar macrophages were cultured in RPMI 1640 medium containing 10% FBS, 100 U/mL of penicillin, and 100 ⁇ g/mL of streptomycin at a condition of 37° C. and 5% CO 2 .
- Cells were placed in a 6-well plate to be at 5 ⁇ 10 5 cells/mL, and a mixture (CFA) that was prepared by dissolving 50 mg/mL of coal and 50 mg/mL of fly ash in DMSO was treated at a concentration of 200 ⁇ g/mL to induce a reaction by fine dust for 1 hour.
- CFA mixture
- Example 4 the Agastache rugosa -only extract (Experimental Example 4), the licorice-only extract (Comparative Example), and the Agastache rugosa and licorice complex extracts (Experimental Examples 1 to 3) prepared in Example 1 above were treated at a concentration of 60 ⁇ g/mL in a solution in which DMSO and PBS were mixed at 1:1 to culture for 6 hours at a condition of 37° C. and 5% CO 2 , respectively.
- a cDNA synthesis kit ReverTraAce cDNA Synthesis kit; Toyobo, Japan.
- the Gr-1+CD11b cell ratio was determined in the lung tissue, in order to confirm whether the Agastache rugosa and licorice complex extract inhibits lung inflammation in vivo.
- a fine dust mixture (CFA) was prepared by mixing 10 mg/mL of coal, 10 mg/mL of fly ash, and 5 mg/mL of a diesel exhaust particle (DEP) mixture, which are components of fine dust, such that the final concentration of alum was 1%.
- the prepared fine dust mixture was directly injected into the airway and nose of the experimental animals by 100 ⁇ L each on day 3, day 6, and day 9 after the start of the experiment using the intranasal tracheal (INT) injection method.
- Comparative Example and Experimental Examples 1 to 4 were diluted with a 0.5% sodium carboxymethyl cellulose (CMC, 419273, Sigma-Aldrich) solution at a concentration of 100 mg/kg and was orally administered every day for 11 days. On day 12 after the start of the experiment, autopsy was performed to analyze lung tissue.
- CMC carboxymethyl cellulose
- a specific fluorescence fluorescent antibody staining method was performed using a CD11b antibody (553310, BD Biosciences, USA) and a Gr-1 antibody (553128, BD Biosciences, USA) with a fluorescent label bound to the lung tissue, and fluorescence-activated cell sorting (FACS, BD Biosciences, USA) was used to measure the ratio of leukocytes (CD11b+/Gr-1+leukocyte) expressing CD11b and Gr-1 among the total leukocytes.
- FACS fluorescence-activated cell sorting
- the MUC5AC mRNA expression levels were determined in the lung tissue, in order to confirm whether sputum production was suppressed by the Agastache rugosa and licorice complex extract.
- RNAzolB Tel-Test, Friendswood, USA
- 2 ⁇ g of the prepared total RNA was placed in 2U/tubeDNase I (AB0620, Thermo Scientific, USA) to react at 37° C. for 30 minutes, and then denatured at 75° C. for 10 minutes.
- 2.5 mL of 10 mM dNTPs mix (4030, TaKaRa, Japan), 1 mL of random sequence hexanucleotides (N8080127, Thermo Scientific, USA), 1 mL of RNase inhibitor (2313A, TaKaRa, Japan), 1 mL of 100 mM DTT (4029, TaKaRa, Japan), and 4.5 mL of 5 ⁇ RTbuffer (M5313, Promega, USA), 4.5 mL of M-MLV RT (M1701, Promega, USA) were added again, and the final volume was adjusted to 20 mL by DEPC-treated distilled water.
- the Agastache rugosa and licorice extract of the present invention has the efficacies of reducing cough, reducing lung inflammation, and suppressing sputum production, and in particular, since it is confirmed that the efficacy of the Agastache rugosa and licorice complex mixture is maximized at a specific mixing ratio, it can be widely utilized as a composition for the prevention or treatment of respiratory diseases caused by fine dust.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for the prevention or treatment of respiratory diseases containing an Agastache rugosa and licorice extract as an active ingredient, and more specifically, the present invention relates to a composition for the prevention or treatment of respiratory diseases caused by fine dust containing an extract, in which Agastache rugosa and licorice are mixed at a weight ratio of 1:1 to 6:1, as an active ingredient.The Agastache rugosa and licorice extract of the present invention has the efficacies of reducing cough through inhibition of TRPV1 activity, reducing lung inflammation through inhibition of CXCR1 and CXCR2 activities and GR-1+CD11b+ cell ratio reduction, and suppressing sputum production through inhibition of MUC5AC activity. In particular, since it is confirmed that the efficacy of the Agastache rugosa and licorice complex mixture is maximized at a specific mixing ratio, it can be widely utilized as a composition for the prevention or treatment of respiratory diseases caused by fine dust.
Description
- This application is a continuation of U.S. patent application Ser. No. 17/257,529, filed Dec. 31, 2020, which is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/KR2020/006617, filed internationally on May 21, 2020, which claims priority to and the benefit of Korean Patent Application No. 10-2020-0020369, filed on Feb. 19, 2020, the disclosures of which are incorporated herein by reference in their entirety.
- The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled FC22276USA.xml, created Sep. 23, 2022, which is 8.84 kilobytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety.
- The present invention relates to a composition for the prevention or treatment of respiratory diseases containing an Agastache rugosa and licorice extract as an active ingredient, and more specifically, the present invention relates to a composition for the prevention or treatment of respiratory diseases caused by fine dust containing an extract, in which Agastache rugosa and licorice are mixed at a weight ratio of 1:1 to 6:1, as an active ingredient.
- Due to the recent development of the industry and economy, the occurrence of respiratory diseases is rapidly increasing due to environmental population and changes in diet. Increased mortality and prevalence due to air pollution is one of the major risks for human health, and the World Health Organization also reported that about 3 million people die each year due to air pollution (approximately 5% of the total deaths), and these effects on the human body are known to be mainly due to fine dust generated during the combustion of fossil fuels.
- Fine dust refers to particulate matter less than 10 μm in diameter (PM10) among the total suspended particles in the air, and it is known to cause diseases such as respiratory diseases, cardiovascular diseases, and the like, and it is also associated with increased mortality. Most of the fine dust is generated by the combustion of fossil fuels, and as it is not filtered by the mucous membrane and cilia of the nose and airways, it penetrates into the alveoli and bronchi to inhibit lung function. Long-term exposure to fine dust causes not only respiratory diseases such as chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, tuberculosis, lung cancer, pulmonary fibrosis, chronic lung diseases, respiratory distress syndrome, upper respiratory tract infection, and the like, but also various diseases such as cardiovascular diseases, skin diseases, and the like.
- When fine dust enters through the respirator tract, it is difficult to discharge, and there is no way to forcefully discharge it. Thus, since it is not exactly known when and what problem will happen with such damage, there is an urgent need for a new therapeutic agent that can prevent, alleviate, treat, or ameliorate damages of the airway and lung induced by fine dust, which is capable of treating respiratory diseases induced thereby.
- As such, in the present invention, as a result of diligently making efforts to develop an effective therapeutic agent for respiratory diseases caused by fine dust, it was confirmed that the efficacy of an Agastache rugosa and licorice extract was maximized at a specific mixing ratio. In particular, the present invention was completed by confirming that lung inflammation, cough, and sputum that characterize the infiltration of neutrophils, which is a respiratory symptom caused by fine dust, were effectively suppressed.
- An object of the present invention is to provide a pharmaceutical composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- Another object of the present invention is to provide a health functional food composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- In order to attain the above-described objects, the present invention provides a pharmaceutical composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- In addition, the present invention provides a health functional food composition for preventing or ameliorating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- According to a preferred exemplary embodiment of the present invention, the respiratory disease may be induced by inhalation of fine dust and may be one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
- According to another preferred exemplary embodiment of the present invention, the Agastache rugosa and licorice extract may be a mixture of an Agastache rugosa extract and a licorice extract, or an Agastache rugosa and licorice complex extract.
- According to another preferred exemplary embodiment of the present invention, the Agastache rugosa and licorice extract may be mixed with Agastache rugosa and licorice at a weight ratio of 1:1 to 6:1.
- According to still another preferred exemplary embodiment of the present invention, the Agastache rugosa and licorice extract may be extracted using one or more solvents selected from the group consisting of water, ethanol, alcohol having a carbon number of 1 to 4. hexane, and ethyl acetate.
- According to still another preferred exemplary embodiment of the present invention, the Agastache rugosa and licorice complex extract may reduce cough through inhibition of TRPV1 activity.
- According to still another preferred exemplary embodiment of the present invention, the Agastache rugosa and licorice complex extract may suppress inflammation in the lungs through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction.
- According to still another preferred exemplary embodiment of the present invention, the Agastache rugosa and licorice complex extract may suppress sputum production through inhibition of MUC5AC activity.
- The Agastache rugosa and licorice extract of the present invention has efficacies of reducing cough through inhibition of TRPV1 activity, reducing lung inflammation through inhibition of CXCR1 and CXCR2 activities and GR-1+CD11b+ cell ratio reduction, and suppressing sputum production through inhibition of MUC5AC activity. In particular, since it is confirmed that the efficacy of the complex mixture of Agastache rugosa and licorice is maximized at a specific mixing ratio, it can be widely utilized as a composition for the prevention or treatment of respiratory diseases caused by fine dust.
-
FIG. 1 is a set of data showing the degree of inhibition of TRPV1 activity according to the mixing ratios of licorice and Agastache rugosa. (A) is data showing the percentage of inhibition of TRPV1 mRNA expression, (B) is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups, and (C) is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa. -
FIG. 2 is a set of data showing the degree of inhibition of CXCR1 activity according to the mixing ratios of licorice and Agastache rugosa. (A) is data showing the percentage of inhibition of CXCR1 mRNA expression, (B) is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups, and (C) is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa. -
FIG. 3 is a set of data showing the degree of inhibition of CXCR2 activity according to the mixing ratios of licorice and Agastache rugosa. (A) is data showing the percentage of inhibition of CXCR2 mRNA expression, (B) is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups, and (C) is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa. -
FIG. 4 is a set of data showing the degree of inhibition of GR-1+CD11b+ cell activity according to the mixing ratios of licorice and Agastache rugosa. (A) is data showing the percentage of inhibition of GR-1+CD11b+ cells, (B) is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups, and (C) is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa. -
FIG. 5 is a set of data showing the degree of inhibition of MUC5AC activity according to the mixing ratios of licorice and Agastache rugosa. (A) is data showing the percentage of inhibition of MUC5AC mRNA expression, (B) is data showing the percentage of inhibition according to the treatment of each extract compared to CFA treatment groups, and (C) is data confirming the synergy effect according to the mixing ratios of licorice and Agastache rugosa. - Hereinafter, the present invention will be described in detail.
- In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- The respiratory disease may be induced by inhalation of fine dust and may be one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, pneumonia, bronchial asthma, bronchiectasis, emphysema, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
- The Agastache rugosa and licorice extract may be mixed with Agastache rugosa and licorice at a weight ratio of 1:1 to 6:1, and preferably, at a weight ratio of 4:1. In addition, while Agastache rugosa and licorice were mixed together to extract (a complex extract) in the present invention, an Agastache rugosa extract and a licorice extract may be prepared separately and then used by mixing depending on the purpose.
- The pharmaceutical composition for preventing or treating a respiratory disease according to the present invention may further include a natural extract that has an effect of preventing, treating, or ameliorating respiratory diseases, a fraction thereof, or a compound thereof, in addition to Agastache rugosa and licorice.
- As a solvent for extracting the Agastache rugosa or licorice, water or an organic solvent such as ethanol or alcohol having a carbon number of 1 to 4. hexane, ethyl acetate, and the like may be used alone in combination. Preferably, the Agastache rugosa and licorice extract of the present invention may be extracted by ethanol.
- In a specific embodiment of the present invention, an Agastache rugosa and licorice extract was prepared using ethanol such that the mixing ratio of Agastache rugosa to licorice was 1:1 to 6:1. respectively, and as Experimental Example 4 and comparative example, an Agastache rugosa-only extract and a licorice-only extract were prepared.
- In another specific embodiment of the present invention, the efficacy of an Agastache rugosa and licorice extract on preventing or ameliorating various respiratory symptoms caused by fine dust was confirmed. First, as a result of confirming the expression level of TRVP-1 known as a cough receptor, it was confirmed that the TRPV1 inhibitory activity was high in the treatment groups of Agastache rugosa and licorice complex extracts (Experimental Examples 1 to 3), compared to an Agastache rugosa-only extract (Experimental Example 4) and a licorice-only extract (Comparative Example). In particular, it was confirmed that the efficacy of suppressing cough was maximized in a complex extract in which Agastache rugosa and licorice were mixed at a ratio of 4:1 (
FIG. 1 ). - In still another specific embodiment of the present invention, as a result of confirming the expression levels of CXCR1 and CXCR2 which are lung inflammatory factors in order to confirm the efficacy of ameliorating the infiltration of neutrophils, which is a characteristic of respiratory diseases caused by fine dust, it was confirmed that the CXCR1 and CXCR2 inhibitory activities were high in the treatment groups of the Agastache rugosa and licorice complex extracts (
Experimental Groups 1 to 3), compared to the Agastache rugosa-only extract (Experimental Example) and the licorice-only extract (Comparative Example) (FIG. 2 andFIG. 3 ). - In addition, as a result of confirming the Gr-1+CD11b cell ratio in lung tissue in order to confirm that the Agastache rugosa and licorice extract suppressed lung inflammation in vivo. it was confirmed that low CD11b+/Gr-1+ leukocyte ratios were shown in the treatment groups of the Agastache rugosa and licorice complex extracts (
Experimental Groups 1 to 3), compared to the Agastache rugosa-only extract (Experimental Example) and the licorice-only extract (Comparative Example) (FIG. 4 ). - That is, since it was confirmed that the Agastache rugosa and licorice extract not only inhibited CXCR1 and CXCR2 expressions, but also significantly reduced the ratio of CD11b+/Gr-1+ cells (neutrophils) in the lung tissue, it was confirmed to have efficacy for ameliorating the infiltration of neutrophils, which is a characteristic of respiratory diseases caused by fine dust.
- In still another specific embodiment of the present invention, as a result of confirming the MUC5AC mRNA expression levels in the lung tissue in order to confirm that sputum production was suppressed by the Agastache rugosa and licorice extract, it was confirmed that the inhibition of MUC5AC activity was high in the treatment groups of the Agastache rugosa and licorice complex extracts (
Experimental Groups 1 to 3), compared to the Agastache rugosa-only extract (Experimental Example 4) and the licorice-only extract (Comparative Example) (FIG. 5 ). - Therefore, since the Agastache rugosa and licorice extract of the present invention can treat or ameliorate respiratory diseases through reducing cough through inhibition of TRPV1 activity; reducing lung inflammation through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction; and suppressing sputum production through inhibition of MUC5AC activity, the Agastache rugosa and licorice extract of the present invention can be widely utilized in the prevention or treatment of respiratory diseases.
- The pharmaceutical composition of the present invention may be formulated into various forms according to respective conventional methods. For example, it may be formulated into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and the like, and may be used in the form of external preparations, suppositories, and sterile injectable solutions. Depending on each formulation, pharmaceutically acceptable carriers, excipients, and diluents may be further included. In addition, it may be formulated and used in the form of external preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like, and sterile injectable solutions according to a conventional method.
- Examples of the carriers, excipients, and diluents include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, mineral oil, and the like. When formulating the pharmaceutical composition or making a dosage form thereof, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like, which are generally used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. These solid preparations are prepared by mixing at least one excipient in the composition, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition, lubricants such as magnesium stearate talc are used in addition to simple excipients. Liquid preparations for oral use may include suspensions, intravenous solutions, emulsions, syrups, and the like, and in addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives, and the like may be included. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations. suppositories, and the like. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases of suppositories, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, and the like may be used.
- As used herein, the term ‘administration’ means to provide the pharmaceutical composition of the present invention to a subject in any suitable way. The pharmaceutical composition of the present invention may be administered at an amount of an active ingredient or a pharmaceutical composition that induces a biological or medical response in a tissue system of an animal or a human, which is considered by researchers, veterinarians, doctors, or other clinicians, that is, at a clinically effective amount which is an amount that induces relief of symptoms of the disease or disorder to be treated. It is apparent to those skilled in the art that the therapeutically effective dose and the number of administrations with respect to the pharmaceutical composition of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered may be easily determined by those skilled in the art, and may be adjusted depending on the type of disease, the severity of the disease, the content of active ingredients and other ingredients contained in the composition, the type of formulation, the patient's age, weight, general health status, gender, and diet, administration time, routes of administration and secretion rates of the composition, treatment period, and various factors including drugs used concurrently. The pharmaceutical composition of the present invention may be administered at an amount of 1 mg/kg/day to 10.000 mg/kg/day, may be administered once a day, or may be divided and administered several times.
- In still another aspect, the present invention relates to a health functional food composition for preventing or ameliorating a respiratory disease containing an Agastache rugosa and licorice extract as an active ingredient.
- Since the Agastache rugosa and licorice extract of the present invention has efficacies of suppressing cough, suppressing lung inflammation through inhibiting the infiltration of neutrophils, and suppressing sputum, it may be used in a health functional food composition for preventing or ameliorating a respiratory disease, which is specifically as described above.
- The formulation of the health functional food of the present invention may be in the form of powders, granules, pills, tablets, and capsules, as well as general foods or beverages.
- The type of the food is not particularly limited, and examples of foods to which the substance may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, and dairy products including ice cream, various soups, beverages, teas, drinks, alcoholic beverages, vitamin complexes, and the like, and may contain all foods in the conventional meanings.
- In general, when preparing a food or beverage, the composition may be added at an amount of 15 parts by weight or less, and preferably, 10 parts by weight or less, based on 100 parts by weight of the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the above amount may be the same or below the above range, and since the composition of the present invention has no problem in terms of safety, it may be used at an amount at or above the above range.
- The beverage among the health functional foods according to the present invention may contain various flavoring agents, natural carbohydrates, or the like, as additional components as in a conventional beverage. The natural carbohydrates described above may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, erythritol, and the like. As the sweetener, natural sweeteners such as thaumatin and a stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like may be used. The ratio of the natural carbohydrate may be about 0.01 g to 0.04 g, and preferably, about 0.02 g to 0.03 g per 100 mL of the beverage according to the present invention.
- In addition to the above, the health functional food according to the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, and carbonating agents used in carbonated beverages. In addition, the composition for improving sleep according to the present invention may contain natural fruit juice, fruit juice drinks, and fruit flesh for the production of vegetable drinks. These ingredients may be used independently or in combination. The ratio of these additives is not limited, but is generally selected from the range of 0.01 to 0.1 parts by weight compared to 100 parts by weight of the health functional food of the present invention.
- Hereinafter, preferred exemplary embodiments are provided to help understanding of the present invention. However, the following examples are only provided to understand the present invention more easily, and the contents of the present invention are not limited by the following examples.
- 1-1: Preparation of Agastache rugosa extract (Experimental Example 4)
- 100 g of dried Agastache rugosa was added to 1.5 L of 30% ethanol and extracted at 70° C. for 4 hours. The extracted sample was filtered under reduced pressure with Whatman No. 2 filter paper, and the filtered extract was concentrated by a vacuum rotary concentrator and dried to prepare an Agastache rugosa extract.
- 1-2: Preparation of Licorice Extract (Comparative Example)
- It was performed in the same manner as in Example 1, except that 100 g of dried licorice was used, and as a result, a licorice extract was prepared.
- 1-3. Preparation of Agastache rugosa and Licorice Extract (Weight Ratio of 1:1) (Experimental Example 1)
- It was performed in the same manner as in Example 1, except that 50 g of dried Agastache rugosa and 50 g of dried licorice were used, and as a result, an Agastache rugosa and licorice extract (ratio of 1:1) was prepared.
- 1-4. Preparation of Agastache rugosa and Licorice Extract (Weight Ratio of 4:1) (Experimental Example 2)
- It was performed in the same manner as in Example 1, except that 80 g of dried Agastache rugosa and 20 g of dried licorice were used, and as a result, an Agastache rugosa and licorice extract (ratio of 4:1) was prepared.
- 1-5. Preparation of Agastache rugosa and Licorice Extract (Weight Ratio of 6:1) (Experimental Example 3)
- It was performed in the same manner as in Example 1, except that 86 g of dried Agastache rugosa and 14 g of dried licorice were used, and as a result, an Agastache rugosa and licorice extract (ratio of 6:1) was prepared.
- In the present invention, the expression level of TRPV-1 known as a cough receptor was determined in order to confirm the cough-reducing efficacy of the Agastache rugosa and licorice extract.
- First, MH-S cells which are alveolar macrophages were cultured in RPMI 1640 medium containing 10% FBS, 100 U/mL of penicillin, and 100 μg/mL of streptomycin at a condition of 37° C. and 5% CO2. Cells were placed in a 6-well plate to be at 5×105 cells/mL, and a mixture (CFA) that was prepared by dissolving 50 mg/mL of coal and 50 mg/mL of fly ash in DMSO was treated at a concentration of 200 μg/mL to induce a reaction by fine dust for 1 hour. Afterwards, the Agastache rugosa-only extract (Experimental Example 4), the licorice-only extract (Comparative Example), and the Agastache rugosa and licorice extracts (Experimental Examples 1 to 3) prepared in Example 1 above were treated at a concentration of 60 μg/mL in a solution in which DMSO and PBS were mixed at 1:1 to culture for 6 hours at a condition of 37° C. and 5% CO2, respectively.
- After culturing for 6 hours, total RNA was isolated by treating a triazole (Ambion TRIzol® reagent; Grand Island, USA), and then cDNA was synthesized using a cDNA synthesis kit (ReverTraAce cDNA Synthesis kit; Toyobo, Japan). By using 100 ng of cDNA, qPCR was performed at a condition of 2 minutes at 50° C., 2 minutes at 95° C., 15 seconds at 95° C. for 40 repetitions, and 1 minute at 60° C. TaqMan-TRPV1 (Mm01246302_m1, FAM-MGB dye-labeled) and GAPDH (Mm99999915_g1, FAM-MGB dye-labeled) were purchased from Thermo Fisher Scientific to perform qPCR.
-
TABLE 1 Synergy effect according to mixing ratios of Agastache rugosa and licorice extracts (TRPV1 inhibitory activity) Mixing Mixing Expected Measured Synergy (measured ratio of amount of Mixing percentage of percentage of percentage of Agastache Agastache amount of inhibition inhibition inhibition/expected rugosa and rugosa licorice (expected (actual percentage of licorice (g) (g) efficacy) efficacy) inhibition) 0:1 0 100 21.0% 21.0% 100.0% 1:0 100 0 21.1% 21.1% 100.0% 1:1 50 50 21.1% 26.2% 124.5% 4:1 80 20 21.0% 34.4% 163.8% 6:1 86 14 21.0% 32.1% 152.6% - The expected percentage of inhibition for the Agastache rugosa and licorice extract was measured according to
Mathematical Formula 1 below. -
Expected percentage of inhibition (%)=[(measured percentage of inhibition of Agastache rugosa-only extract (%))×mixing amount of Agastache rugosa (g)/100]+[(measured percentage of inhibition of licorice-only extract (%))×mixing amount of licorice (g)/100] [Mathematical Formula 1] - As a result, as shown in
FIG. 1 , it was confirmed that the TRPV1 activities were reduced in all the treatment groups of the Agastache rugosa-only extract, the licorice-only extract, and the Agastache rugosa and licorice extracts, compared to CFA treatment groups, and in particular, it was confirmed that the TRPV1 inhibitory activity was high in the Agastache rugosa and licorice extracts (Experimental Examples 1 to 3) compared to the treatment groups of the Agastache rugosa-only extract (Experimental Example 4) and the licorice-only extract (Comparative Example). This means that the Agastache rugosa and licorice extracts of the present invention reduce the activity of TRPV1 and thus, the effect of reducing cough by fine dust is excellent. - In addition, as shown in Table 1, it was confirmed that the TRPV1 inhibitory activity was increased depending on the mixing of the Agastache rugosa extract and the licorice extract, and in particular, it was confirmed that the TRPV1 inhibitory activity was most excellent when the Agastache rugosa and licorice extract was mixed at a weight ratio of 4:1.
- In the present invention, CXCR1 and CXCR2 expression levels were determined in order to confirm whether the Agastache rugosa and licorice complex extract inhibits lung inflammation.
- First, MH-S cells which are alveolar macrophages were cultured in RPMI 1640 medium containing 10% FBS, 100 U/mL of penicillin, and 100 μg/mL of streptomycin at a condition of 37° C. and 5% CO2. Cells were placed in a 6-well plate to be at 5×105 cells/mL, and a mixture (CFA) that was prepared by dissolving 50 mg/mL of coal and 50 mg/mL of fly ash in DMSO was treated at a concentration of 200 μg/mL to induce a reaction by fine dust for 1 hour. Afterwards, the Agastache rugosa-only extract (Experimental Example 4), the licorice-only extract (Comparative Example), and the Agastache rugosa and licorice complex extracts (Experimental Examples 1 to 3) prepared in Example 1 above were treated at a concentration of 60 μg/mL in a solution in which DMSO and PBS were mixed at 1:1 to culture for 6 hours at a condition of 37° C. and 5% CO2, respectively.
- After culturing for 6 hours, total RNA was isolated by treating a triazole (Ambion TRIzol® reagent; Grand Island, USA), and then cDNA was synthesized using a cDNA synthesis kit (ReverTraAce cDNA Synthesis kit; Toyobo, Japan). By using 100 ng of cDNA and primers of Table 2 below, qPCR was performed at conditions of 2 minutes at 50° C., 2 minutes at 95° C., 15 seconds at 95° C. for 40 repetitions, and 1 minute at 60° C.
-
TABLE 2 Primer sequences Name of SEQ target gene Primer sequences (5′→3′) ID NO CXCR1 Forward direction AATCTGTTGTGGCTTCACCCA 1 Reverse direction GCTATCTTCCGCCAGGCATAT 2 CXCR2 Forward direction AGCAAACACCTCTACTACCCTCTA 3 Reverse direction GGGCTGCATCAATTCAAATACCA 4 GAPDH Forward direction TGAAGCAGGCATCTGAGGG 5 Reverse direction CGAAGGIGGAAGAGTGGGAG 6 -
TABLE 3 Inhibition of CXCR1 activity according to mixing ratios of Agastache rugosa and licorice extracts Mixing Mixing Expected Measured Synergy (measured ratio of amount of Mixing percentage of percentage of percentage of Agastache Agastache amount of inhibition inhibition inhibition/expected rugosa and rugosa licorice (expected (actual percentage of licorice (g) (g) efficacy) efficacy) inhibition) 0:1 0 100 32.1% 32.1% 100.0% 1:0 100 0 78.4% 78.4% 100.0% 4:1 80 20 69.1% 79.5% 115.0% -
TABLE 4 Inhibition of CXCR2 activity according to mixing ratios of Agastache rugosa and licorice extracts Mixing Mixing Expected Measured Synergy (measured ratio of amount of Mixing percentage of percentage of percentage of Agastache Agastache amount of inhibition inhibition inhibition/expected rugosa and rugosa licorice (expected (actual percentage of licorice (g) (g) efficacy) efficacy) inhibition) 0:1 0 100 −2.2% −2.2% 100.0% 1:0 100 0 9.3% 9.3% 100.0% 4:1 80 20 7.0% 20.5% 264.6% - As a result, as shown in
FIG. 2 ,FIG. 3 , Table 3, and Table 4, it was confirmed that the CXCR1 and CXCR2 activities were reduced in all of the treatment groups of the Agastache rugosa-only extract, the licorice-only extract, and the complex extracts compared to CFA treatment groups, and in particular, it was confirmed that the CXCR1 and CXCR2 inhibitory activities were high in the treatment groups of the Agastache rugosa and licorice complex extracts (Experimental Examples 1 to 3) compared to the Agastache rugosa-only extract (Experimental Example 4) and the licorice-only extract (Comparative Example). This means that the Agastache rugosa and licorice complex extract of the present invention has an excellent effect of reducing inflammation in the lungs by lowering neutrophil chemotaxis through inhibitions of CXCR1 and CXCR2 activities. - In the present invention, the Gr-1+CD11b cell ratio was determined in the lung tissue, in order to confirm whether the Agastache rugosa and licorice complex extract inhibits lung inflammation in vivo.
- First, with 8 Balb/c male mice per group, in all groups excluding the normal group, a fine dust mixture (CFA) was prepared by mixing 10 mg/mL of coal, 10 mg/mL of fly ash, and 5 mg/mL of a diesel exhaust particle (DEP) mixture, which are components of fine dust, such that the final concentration of alum was 1%. The prepared fine dust mixture was directly injected into the airway and nose of the experimental animals by 100 μL each on day 3,
day 6, and day 9 after the start of the experiment using the intranasal tracheal (INT) injection method. - Comparative Example and Experimental Examples 1 to 4 were diluted with a 0.5% sodium carboxymethyl cellulose (CMC, 419273, Sigma-Aldrich) solution at a concentration of 100 mg/kg and was orally administered every day for 11 days. On day 12 after the start of the experiment, autopsy was performed to analyze lung tissue.
- A specific fluorescence fluorescent antibody staining method was performed using a CD11b antibody (553310, BD Biosciences, USA) and a Gr-1 antibody (553128, BD Biosciences, USA) with a fluorescent label bound to the lung tissue, and fluorescence-activated cell sorting (FACS, BD Biosciences, USA) was used to measure the ratio of leukocytes (CD11b+/Gr-1+leukocyte) expressing CD11b and Gr-1 among the total leukocytes.
-
TABLE 5 Inhibitory activity of CD11b+/Gr-1+ cell ratios according to the mixing ratios of Agastache rugosa and licorice extracts Mixing Mixing Expected Measured Synergy (measured ratio of amount of Mixing percentage of percentage of percentage of Agastache Agastache amount of inhibition inhibition inhibition/expected rugosa and rugosa licorice (expected (actual percentage of licorice (g) (g) efficacy) efficacy) inhibition) 0:1 0 100 20.6% 20.6% 100.0% 1:0 100 0 17.4% 17.4% 100.0% 4:1 80 20 19.96% 42.9% 237.7% - As a result, as shown in
FIG. 4 and Table 5, it was confirmed that the ratios of CD11b+/Gr-1+ leukocytes were reduced in all of the treatment groups of the Agastache rugosa-only extract, the licorice-only extract and the complex extracts compared to CFA treatment groups, and in particular, it was confirmed that lower CD11b+Gr-1+ leukocyte ratios were exhibited in the treatment groups of the Agastache rugosa and licorice complex extracts (Experimental Examples 1 to 3) compared to the Agastache rugosa-only extract (Experimental Example 4) and the licorice-only extract (Comparative Example). That is, it was confirmed that the Agastache rugosa and licorice complex extract showed remarkable inhibitory activity for bronchial inflammation. - In the present invention, the MUC5AC mRNA expression levels were determined in the lung tissue, in order to confirm whether sputum production was suppressed by the Agastache rugosa and licorice complex extract.
- First, 500 mL of RNAzolB (Tel-Test, Friendswood, USA) was added to the lung tissue extracted in Example 4 above and pulverized until dissolved. After adding 50 mL of CHCl3 to the mixed suspension, it was mixed again for 15 seconds. It was left on ice for 15 minutes and centrifuged at 13,000 rpm. About 200 mL of the supernatant was recovered and the same amount of 2-propanol (I9516, Sigma-Aldrich. USA) was mixed, slowly shaken, and left on ice for 15 minutes. It was centrifuged again at 13,000 rpm, washed with 80% ethanol, and dried in vacuum for 3 minutes to extract RNA. The extracted RNA was dissolved in 20 mL of distilled water treated with diethyl pyrocarbonate (DEPC, 750023, Thermo Scientific, USA), inactivated at 75° C., and used for cDNA synthesis.
- 2 μg of the prepared total RNA was placed in 2U/tubeDNase I (AB0620, Thermo Scientific, USA) to react at 37° C. for 30 minutes, and then denatured at 75° C. for 10 minutes. After adding 2.5 mL of 10 mM dNTPs mix (4030, TaKaRa, Japan), 1 mL of random sequence hexanucleotides (N8080127, Thermo Scientific, USA), 1 mL of RNase inhibitor (2313A, TaKaRa, Japan), 1 mL of 100 mM DTT (4029, TaKaRa, Japan), and 4.5 mL of 5×RTbuffer (M5313, Promega, USA), 4.5 mL of M-MLV RT (M1701, Promega, USA) were added again, and the final volume was adjusted to 20 mL by DEPC-treated distilled water. After mixing well, the mixture was centrifuged at 2,000 rpm for 5 seconds and reacted for 60 minutes in a 37° C. heating block (Multi-blok heater, TRIPUNITHURA, USA) to synthesize cDNA. Then, it was left at 95° C. for 5 minutes, and synthesized cDNA was used for PCR by inactivating M-MLV RT. Sper-Taqman PCR Master mix (4304437, Applied Biosystems, USA) was used, and it was reacted such that the final concentration of the primer (refer to Table 6) was 200 nM. For the conditions of RT-PCR, predenaturation was performed at 50° C. for 2 minutes, 94° C. for 10 minutes, and 95° C. for 0.15 minutes for 40 cycles, and 60° C. for 1 minute. GAPDH (4352339E, Thermo Scientific, USA) was used as the internal standard.
-
TABLE 6 Primer sequences Name of SEQ target gene Primer sequences (5′→3′) ID NO MUC5AC Forward direction AGAATATCTTTCAGGACCCCTGCT 7 Reverse direction ACACCAGTGCTGAGCATACTTTT 8 GAPDH-VIC Probe CATGTTCCAGTATGACTCCACTCACG 9 -
TABLE 7 Inhibition of MUC5AC activity according to the mixing ratios of Agastache rugosa and licorice extracts Mixing Mixing Expected Measured Synergy (measured ratio of amount of Mixing percentage of percentage of percentage of Agastache Agastache amount of inhibition inhibition inhibition/expected rugosa and rugosa licorice (expected (actual percentage of licorice (g) (g) efficacy) efficacy) inhibition) 0:1 0 100% 35.7% 35.7% 100.0% 1:0 100% 0 45.0% 45.0% 100.0% 4:1 80% 20% 41.9% 64.5% 149.4% - As a result, as shown in
FIG. 5 and Table 7, it was confirmed that the expression levels of MUC5AC gene were reduced in all of the treatment groups of the Agastache rugosa-only extract, the licorice-only extract, and the complex extracts compared to CFA treatment groups, and in particular, it was confirmed that the MUC5AC inhibitory activities were higher in the treatment groups of the Agastache rugosa and licorice complex extracts (Experimental Examples 1 to 3) compared to the Agastache rugosa-only extract (Experimental Example 4) and the licorice-only extract (Comparative Example). That is, it was confirmed that the Agastache rugosa and licorice complex extract suppressed sputum production. - The Agastache rugosa and licorice extract of the present invention has the efficacies of reducing cough, reducing lung inflammation, and suppressing sputum production, and in particular, since it is confirmed that the efficacy of the Agastache rugosa and licorice complex mixture is maximized at a specific mixing ratio, it can be widely utilized as a composition for the prevention or treatment of respiratory diseases caused by fine dust.
Claims (13)
1.-8. (canceled)
9. A pharmaceutical composition for preventing, ameliorating, or treating a respiratory disease, comprising an Agastache rugosa extract as an active ingredient.
10. The pharmaceutical composition of claim 9 , wherein the respiratory disease is induced by inhalation of fine dust and is one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, emphysema, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
11. The pharmaceutical composition of claim 9 , wherein the Agastache rugosa extract reduce cough through inhibition of TRPV1 activity, reduce lung inflammation through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction, or suppress sputum production through inhibition of MUC5AC activity.
12. A health functional food product for preventing or ameliorating a respiratory disease, comprising an Agastache rugosa extract.
13. The health functional food product of claim 12 , wherein the respiratory disease is induced by inhalation of fine dust and is one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, emphysema, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
14. The health functional food product of claim 12 , wherein the Agastache rugosa extract reduce cough through inhibition of TRPV1 activity, reduce lung inflammation through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction, or suppress sputum production through inhibition of MUC5AC activity.
15. A method for preventing, ameliorating, or treating a respiratory disease, comprising administering an Agastache rugosa extract to a subject in need thereof at an effective amount.
16. The method of claim 15 , wherein the respiratory disease is induced by inhalation of fine dust and is one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, emphysema, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
17. The method of claim 15 , wherein the Agastache rugosa extract reduce cough through inhibition of TRPV1 activity, reduce lung inflammation through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction, or suppress sputum production through inhibition of MUC5AC activity.
18. A method for producing the health functional food product for preventing or ameliorating a respiratory disease of claim 12 , comprising preparing an Agastache rugosa extract; and making the health functional food product with the extract.
19. The method of claim 18 , wherein the respiratory disease is induced by inhalation of fine dust and is one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, emphysema, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.
20. The method of claim 18 , wherein the Agastache rugosa extract reduce cough through inhibition of TRPV1 activity, reduce lung inflammation through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction, or suppress sputum production through inhibition of MUC5AC activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/935,043 US20230270811A1 (en) | 2020-02-19 | 2022-09-23 | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising agastache rugosa and licorice extract |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200020369A KR102131602B1 (en) | 2020-02-19 | 2020-02-19 | A composition for the prevention or treatment of respiratory diseases caused by fine dust containing agastache rugosa and licorice extract |
| KR10-2020-0020369 | 2020-02-19 | ||
| US17/257,529 US11980649B2 (en) | 2020-02-19 | 2020-05-21 | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising Agastache rugosa and licorice extract |
| PCT/KR2020/006617 WO2021167168A1 (en) | 2020-02-19 | 2020-05-21 | Composition, containing agastache rugosa and licorice extract as active ingredient, for preventing or treating respiratory diseases caused by fine dust |
| US17/935,043 US20230270811A1 (en) | 2020-02-19 | 2022-09-23 | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising agastache rugosa and licorice extract |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/257,529 Continuation US11980649B2 (en) | 2020-02-19 | 2020-05-21 | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising Agastache rugosa and licorice extract |
| PCT/KR2020/006617 Continuation WO2021167168A1 (en) | 2020-02-19 | 2020-05-21 | Composition, containing agastache rugosa and licorice extract as active ingredient, for preventing or treating respiratory diseases caused by fine dust |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20230270811A1 true US20230270811A1 (en) | 2023-08-31 |
Family
ID=71601449
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/257,529 Active US11980649B2 (en) | 2020-02-19 | 2020-05-21 | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising Agastache rugosa and licorice extract |
| US17/935,043 Pending US20230270811A1 (en) | 2020-02-19 | 2022-09-23 | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising agastache rugosa and licorice extract |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/257,529 Active US11980649B2 (en) | 2020-02-19 | 2020-05-21 | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising Agastache rugosa and licorice extract |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11980649B2 (en) |
| KR (1) | KR102131602B1 (en) |
| CN (2) | CN115887524A (en) |
| AU (1) | AU2020294219B9 (en) |
| WO (1) | WO2021167168A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102355106B1 (en) * | 2020-03-08 | 2022-01-26 | 충남대학교산학협력단 | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease |
| KR20230060553A (en) | 2021-10-27 | 2023-05-08 | 농업회사법인 주식회사 네이처포스 | Phamaceutical composition consisting of medicinal herbs extracts for preventing and treating the respiratory disease causing particulate watter in the air |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020013134A (en) | 2000-08-11 | 2002-02-20 | 박찬우 | Immune Modulator and food containing the same |
| KR20030007243A (en) * | 2002-10-02 | 2003-01-23 | 김경렬 | Phamaceutical composition comprising COCICIS SEMEN, MORI COTEX RADICIS, HOUTTUYNIA CORDATA, PLATYCODI RADIX, REHMANNIAE RADIX, LONICERAE FLOS, SAURURUS CHINESIS LOUR BAIL, ZINGIBER OFFICINALE ROSCOE, PAEONIAE RADIX RUBRA as main ingredients |
| CN101564460A (en) * | 2008-04-24 | 2009-10-28 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating chronic obstructive pulmonary disease |
| KR101229254B1 (en) | 2009-11-09 | 2013-02-26 | 황성연 | Composition for immune enhancement comprising the extract of Young antler, Ligusticum acutilobum, Cornus officinalis, Chinese matrimony vine, Curcuma aromatica Salisb, Yam, Aurantii nobilis pericarpium, Agastache rugosa, Gastrodia elata blume, Cinnamomum loureirii, Schizandra chinensis, Ginseng steamed red, snake's beard and citrus powder, as active ingredient |
| CN102132916A (en) * | 2010-12-20 | 2011-07-27 | 胡彬 | Herbal health-care beverage |
| KR101390122B1 (en) | 2012-03-30 | 2014-05-07 | 정길동 | Manufacture method of health food pill |
| KR20130133610A (en) * | 2012-05-29 | 2013-12-09 | 한국식품연구원 | Anti-allergy compositions comprising natural extracts as active ingredients |
| CN103766751B (en) * | 2014-01-24 | 2016-02-03 | 赵杏珍 | The medicine food of the breathing problem that control haze causes and lung cancer is with meals face |
| CN106070838A (en) * | 2016-06-12 | 2016-11-09 | 张俊辉 | The manufacture method of Usnea balm flower health tea |
| WO2018124508A1 (en) | 2016-12-30 | 2018-07-05 | 연세대학교 산학협력단 | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
| CN107050323A (en) * | 2017-01-26 | 2017-08-18 | 赵杏珍 | A kind of anti-fog haze lung-heat clearing and detoxification drink of integration of drinking and medicinal herbs Chinese herb prevention |
| KR102082106B1 (en) | 2019-06-03 | 2020-02-27 | 코스맥스엔비티 주식회사 | Method for preparing noni fruit extract containing high iridoids content and immune-enhancing composition comprising noni fruit extract or fraction thereof |
-
2020
- 2020-02-19 KR KR1020200020369A patent/KR102131602B1/en active IP Right Grant
- 2020-05-21 AU AU2020294219A patent/AU2020294219B9/en active Active
- 2020-05-21 US US17/257,529 patent/US11980649B2/en active Active
- 2020-05-21 WO PCT/KR2020/006617 patent/WO2021167168A1/en active Application Filing
- 2020-05-21 CN CN202211243025.5A patent/CN115887524A/en active Pending
- 2020-05-21 CN CN202080001215.9A patent/CN113543794B/en active Active
-
2022
- 2022-09-23 US US17/935,043 patent/US20230270811A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113543794B (en) | 2023-01-03 |
| AU2020294219B2 (en) | 2023-04-06 |
| WO2021167168A1 (en) | 2021-08-26 |
| AU2020294219A1 (en) | 2021-09-02 |
| US20230210932A1 (en) | 2023-07-06 |
| KR102131602B1 (en) | 2020-07-08 |
| AU2020294219B9 (en) | 2023-04-13 |
| CN113543794A (en) | 2021-10-22 |
| CN115887524A (en) | 2023-04-04 |
| US11980649B2 (en) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230270811A1 (en) | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising agastache rugosa and licorice extract | |
| JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
| KR102160413B1 (en) | A composition for the prevention or treatment of respiratory diseases caused by fine dust containing agastache rugosa extract | |
| EP3040078A1 (en) | Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent | |
| JPWO2002072123A1 (en) | Prophylactic or therapeutic agent for tumor or human papillomavirus disease | |
| KR101621863B1 (en) | Composition for preventing or treating chronic obstructive pulmonary diseases comprising monoacetyldiacylglycerol compound | |
| JP2023525322A (en) | Discovery of novel Akkermansia muciniphila AK32 strains and their application for the prevention or treatment of intestinal damage | |
| KR102147801B1 (en) | Pharmaceutical composition comprising fermented extract of peppermint for preventing or treating of respiratory diseases | |
| KR101899555B1 (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
| KR101521341B1 (en) | Composition for prevention or treatment of anorexia comprising menispermum dauricum DC, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperum dauricum DC malt fermented liquid extract | |
| KR102351651B1 (en) | Composition for Prevention, Improvement or Treatment of Fine Dust Stimulation Respiratory Disease comprising Mixture of Natural Origin | |
| KR20190080239A (en) | Composition for Improving Sleep Disorders containing Fermentated Dendropanax morbifera and L-Serine | |
| JP2013177369A (en) | Nitrogen monoxide production inhibitor | |
| CN112674327B (en) | Health-care food | |
| KR20180118412A (en) | Composition comprising Cordycepin as an effective ingredient for preventing or treating of Liver cancer and Method for preparing Ethyl acetate fraction of Cordyceps militaris | |
| KR20240026577A (en) | Composition for protecting respiratory organ against fine dust comprising fermented Wongam extract as effective component | |
| KR20240011614A (en) | Composition for preventing or treating respiratory diseases comprising Nelumbo nucifera leaf extract | |
| KR20220076384A (en) | Health functional food composition for increasing muscle strength containing mealworm protein and lactic acid bacteria dead cells as active ingredients | |
| JP2017095409A (en) | Muscle atrophy inhibitor and food and medicine comprising the same | |
| KR101481040B1 (en) | Composition for anti-inflammation comprising [10]-gingerdione or 1-dehydro-[10]-gingerdione | |
| KR20230019398A (en) | Antivirus composition and use thereof | |
| KR20230098052A (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Lysimachia mauritiana extract as effective component | |
| EP3766509A1 (en) | Crude drug composition for preventing or treating respiratory diseases | |
| KR20230040175A (en) | Composition for preventing, alleviating, or treating diabetes comprising Artemisiae argyi extract as an active ingredient | |
| WO2010116834A1 (en) | Process for production of orally ingestible composition containing arabinosyl vitexin, and use of the composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |